Pharmaceutical
Maroon Biotech has proprietary surfactant compounds in the development pipeline that could greatly improve outcomes for survivors of military trauma, spinal cord compression, and malignant hyperthermia. Maroon Biotech also has compositions available for licensing that will enhance gene transfection efficacy and reduce reperfusion injury following myocardial infarction or stroke. Here are some of our formulations. Maroon is continually expanding its library of surfactant copolymers in addition to developing these formulations, which are protected by company intellectual property.
Poloxafuse-R™
Poloxafuse-R™ is a formulation under development that is designed to address cell injury in instances of ischemia followed by reperfusion. Situations where this condition would arise include myocardial infarction, stroke, and surgical transplantation procedures. Poloxafuse-R™ comprises a synthetic, biocompatible surfactant copolymer that is capable of sealing porated cell membranes and a free radical scavenger to eliminate harmful reactive oxygen species generated during ischemia/reperfusion events.
Poloxafuse-T™
Poloxafuse-T™ is a formulation under development that is designed to enhance the transfection of therapeutic entities into targeted cells. Poloxafuse-T™ comprises a synthetic, biocompatible surfactant copolymer that is capable of interacting with cell membranes, facilitating the ingress of exogenous biomacromoleclues and later to seal the same membranes; DNA, proteins, antisense genes, or other molecules that require delivery into cell interiors; and cofactors that improve efficacy of the process.
Poloxafuse-I™
Poloxafuse-I™ is a formulation under development that is designed to address cell injury for instances of general trauma where a common pathology is damage to the cell membrane. These include, but are not limited to, burn, electrical, radiological, and other chemical, biochemical, and physical injuries. Poloxafuse-I™ comprises a synthetic, biocompatible surfactant copolymer that is capable of sealing porated cell membranes and other compounds that provide specific benefits to the condition being treated. These other compounds may include free radical scavengers, cofactors to stabilize cell function, commercially available pharmaceuticals, and others.